The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents

NCT06854328 | Recruiting DMC FDA Device

• 1 other identifier: CLP008
• Study Type: interventional
• Target: 45
• Locations: 2 countries
• Sites: 2

Brief Summary

Prism is a software as a medical device (SaMD) to be prescribed by clinicians as an adjunct to the standard of care treatment of patients with PTSD. The Prism software device runs on a laptop using an EEG signal input (g).Nautilos PRO (K171669). The primary objective of the study is to extend the use of the FDA cleared Prism for PTSD (K222101) to an adolescent population and to confirm the safety of fifteen (15±3) EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms in adolescents. The study aims to demonstrate the safety profile of Prism, having no device-related serious adverse events (SAEs), consistent with findings in the adult population, throughout the course of Prism treatment in an adolescent population.

Conditions

Post-Traumatic Stress Disorder in Adolescence

Keywords

Neurofeedback; PTSD in adolescent

Outcome Measures

Primary Outcomes (1)

• Safety reporting

  The primary objective of the study is to extend the use of the FDA cleared Prism for PTSD (K222101) to an adolescent population and to confirm the safety of Prism, by closely following and analyzing device-related serious adverse events. The success criterion is defined by no serious adverse event which is deemed as device-related during the study and one month after treatment ends.

  1 month

Secondary Outcomes (2)

• Proportion of participants improved in CAPS-5

  9 weeks

• Proportion of participants improved in PCL-5

  9 weeks

Study Arms (1)

Single arm

EXPERIMENTAL

Eligible participants diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training. Participants will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.

Device: Prism

Interventions

Prism DEVICE

Prism is using an amygdala-fMRI-guided model for processing EEG signals. The model, termed EEG fMRI pattern (EFP), uses several electrodes EEG-signal to produce a real time amygdala-EFP biomarker signal. GrayMatters' product, Prism, is used to train patients in downregulating the amygdala-derived-EFP biomarker during therapy sessions.

Single arm

Eligibility Criteria

• Age: 12 Years - 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Ages 12 to 21 years.
• Any gender.
• Diagnosis of PTSD, established according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
• ≥1 year since index trauma.
• For candidate participants under 18 years old: Willingness and ability to provide assent, with the participant's legal guardian able and willing to provide informed consent for their study participation.
• For candidate participants 18 years old and above: Willingness and ability to provide informed consent for their study participation.
• English speaking, writing and reading.
• Normal or corrected-to-normal vision and hearing.

You may not qualify if:

• Have completed one or more full courses of trauma-focused therapy in the past (i.e., Eye Movement Desensitization and Reprocessing \[EMDR\], Prolong Exposure Therapy etc.), eligibility will be deemed upon the clinical judgement of the investigator.
• Diagnosis for schizophrenia, schizoaffective disorder, schizophreniform disorder, Bipolar I disorder, or delusional disorder.
• Any mood or anxiety disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), that has been the primary focus of mental health treatment within the 6 months prior to screening, based on the clinical judgment of the site investigator.
• Diagnosis of autism spectrum requiring substantial support, intellectual disability of mild severity at discretion of investigator.
• Diagnosis of moderate or severe substance use disorder within the last 3 months of the screening visit (as defined in DSM-5-substance use disorder) or at the screening visit.
• Current symptom level of moderate or severe ADHD (as defined in DSM-5 ADHD disorder) or at screening visit.
• Any change in- or initiation of- psychotropic medications within the past 4 weeks. At the time of recruitment, subjects must have no intention of changing their medication or psychotherapy during the study duration.
• Any suicidal behavior within the past 1 year (i.e., actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior), prior to screening and during the screening period.
• Recent initiation (within the past 3 months) of cognitive-behavioral therapy or any evidence-based PTSD psychotherapy (Cognitive Processing Therapy \[CPT\], Prolonged Exposure \[PE\], Eye Movement Desensitization and Reprocessing \[EMDR\]). However, continuation of established maintenance supportive therapy will be permitted.
• Any history of brain surgery, of penetrating, neurovascular, infectious, or other major brain injury, of epilepsy, or of other major neurological abnormality (including a history of traumatic brain injury \[TBI\] with loss of consciousness for more than 24 hours or posttraumatic amnesia for more than 7 days).
• Any unstable medical condition, as per the clinical judgement of the investigator.
• Enrollment in another interventional clinical study at screening or within 2 months prior to screening or intended enrollment within the duration of this study.
• Female subjects who are pregnant, nursing, or who plan to become pregnant while in the trial.

Sponsors & Collaborators

• GrayMatters Health Ltd.: lead

Study Sites (2)

NYU Langone Health

New York, New York, 10016, United States

RECRUITING

Sheba Medical Center

Ramat Gan, 3303403, Israel

RECRUITING

Study Officials

• ADAR SHANI

  GrayMatters Health

  STUDY DIRECTOR

Central Study Contacts

Jennifer Yarden

CONTACT

+972-524897823; jennifer@graymatters-health.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 24, 2025
• First Posted: March 3, 2025
• Study Start: June 11, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: May 5, 2026

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1); IL (1)